About AN Venture Partners
AN Venture Partners is a venture capital firm founded in 2022. It is primarily based out of San Francisco, United States. As of Sep 2026, AN Venture Partners is an active investor, having invested in 7 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of Typewriter Therapeutics A lot of funds co-invest with AN Venture Partners, with names like RA Capital Management sharing a substantial percentage of its portfolio. AN Venture Partners has team of 13 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 1 more
Portfolio Soonicorns
Deals in last 12 months
AN Venture Partners' List of Top Investments
AN Venture Partners has a portfolio of 7 companies. Their most notable investments are in Typewriter Therapeutics and Typewriter Therapeutics.Their portfolio spans across and United States. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Series A, Seed and 1 more. Here is the list of top investments by AN Venture Partners:
Imbria Pharmaceuticals provides therapeutics solution by translation the cellular metabolism. It is involved in providing transformative medicine, by altering the cellular metabolism and mitochondrial function.
Key facts about Imbria Pharmaceuticals
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $157M
- Investors: RA Capital Management, Deep Track Capital and 6 Others
- Latest Funding Round: Series B, Nov 17, 2025, $*****
- Highlight: Editors' Pick
Developer of gene therapies for multiple diseases. It offers RNAi therapeutics based on next-generation engineering of small interfering RNAs for patients across multiple disease indications.
Key facts about City Therapeutics
- Founded Year: 2006
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $234M
- Employee Count: 85 as on Jul 31, 2026
- Investors: Fidelity Investments, Rock Springs Capital and 9 Others
- Latest Funding Round: Series B, Jun 08, 2026, $*****
- Highlight: Editors' Pick
3. Crystalystx
Developer of a URAT1 inhibitor for the treatment of gout. The company focuses on advancing its lead candidate into global Phase 3 trials. The candidate is intended as a second-line therapy. It is supported by clinical data from approvals in Asian markets.
Key facts about Crystalystx
- Founded Year: 2022
- Location: San Diego (United States)
- Stage: Series B
- Total Funding till date: $335M
- Investors: Frazier Life Sciences, Cormorant-asset and 19 Others
- Latest Funding Round: Series B, Jul 22, 2026, $*****
Developer of pharmaceutical therapies for patients with various neurological disorders. Research efforts focus on identifying and testing chemical compounds to address complex brain conditions. The organization conducts clinical trials to evaluate the safety and efficacy of potential treatments for neurological and neuropsychiatric health issues. These activities involve the systematic investigation of biological pathways to facilitate the creation of medicinal products.
Key facts about Tortugas Neuroscience
- Founded Year: 2024
- Location: Framingham (United States)
- Stage: Series A
- Total Funding till date: $106M
- Investors: The Column Group, Cure Ventures and 1 Other
- Latest Funding Round: Seed, Apr 24, 2026, $*****
Developer of gene therapies for genetic disorders. It offers ribonucleic acid based gene writing therapeutic platform for developing therapies for patients suffering from diseases with limited or no clinical options.
Key facts about Typewriter Therapeutics
- Founded Year: 2022
- Location: Cambridge (United States)
- Stage: Series A
- Total Funding till date: $61M
- Employee Count: 34 as on Jul 31, 2026
- Investors: RA Capital Management, ANRI and 2 Others
- Latest Funding Round: Series A, Sep 02, 2026, $*****
AN Venture Partners' Year-on-Year Investment Trends
In 2025, it made 3 investments, while as of Sep 2026, it has made 4 investments in this year. Its most recent first time investment was in Tortugas Neuroscience and most recent follow-on round was in Typewriter Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 3 | 4 |
2025 | 3 | 0 | 3 |
2024 | 2 | 0 | 2 |
AN Venture Partners' Investments by Stage
AN Venture Partners has made 3 investments in Series A stage with an average round size of $170M, 2 investments in Seed stage with an average round size of $9.5M and 1 investment in Series B stage with an average round size of $66.7M.Stage of entry | No. of Investments |
|---|---|
Series A | 3 |
Seed | 2 |
Series B | 1 |
Note: We have considered here, only first round of investments
AN Venture Partners' Investments by Sector
AN Venture Partners has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications and High Tech. Notably, it has invested in 4 Enterprise (B2B) companies, 4 Tech companies and 1 Software company.Sector | No. of Investments |
|---|---|
Life Sciences | 6 |
Enterprise Applications | 1 |
High Tech | 1 |
Note: We have considered here, only first round of investments
AN Venture Partners' Investments by Geography
AN Venture Partners has made most investments in United States (6).AN Venture Partners' recent investments
AN Venture Partners has made 4 investments in 2026 so far. Typewriter Therapeutics and Crystalystx are the latest among them.Here are the most recent investments by AN Venture Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 02, 2026 | United States | Series A | 7378 | ||
Jul 22, 2026 | United States | Series B | 2967 | [+19] | |
Jun 08, 2026 | United States | Series B | 7821 | [+9] | |
Apr 24, 2026 | United States | Series A | 6536 | [+1] | |
Sep 30, 2025 | United States | Series A | 8305 | [+10] |
Team profile of AN Venture Partners
AN Venture Partners has a team of 13 members including 3 Partners, 1 Venture Partner and 1 Principal located in Japan and United States. AN Venture Partners' team does not sit on the board of any company as of now.Here is a list of top team members in AN Venture Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Japan | - | ||
Partner | - | - | ||
Partner | Tokyo | - | ||
Venture Partner | Chicago | - | ||
Principal | Tokyo | - |
Co-investors of AN Venture Partners
Over the past 2 years, 43 investors have co-invested in AN Venture Partners's portfolio companies. This includes only funds.
- Invested before AN Venture Partners: RA Capital Management and Sanofi Ventures have invested in rounds before AN Venture Partners. There is 1 company where RA Capital Management has invested before AN Venture Partners and 1 company where Sanofi Ventures has invested before AN Venture Partners.
- Top Co-investors of AN Venture Partners: 26 investors entered a company along with AN Venture Partners. These include investors like RA Capital Management (2 companies).
- Invested after AN Venture Partners: A total of 15 investors have invested in AN Venture Partners's portfolio after their investments. Top Investors include AXA Investment Managers (1 company), Sofinnova Investments (1 company) and Viking Global Investors (1 company).
Recent News related to AN Venture Partners
•
Typewriter Therapeutics Raises $56M in Series A FundingFinSMEs•Sep 02, 2026•AN Venture Partners, RA Capital Management, Typewriter Therapeutics, Gemseki Investment and 1 other
•
•
Imbria Pharmaceuticals Extends Series B Financing for Ninerafaxstat DevelopmentBenzinga•Nov 17, 2025•Explorer Ventures, Imbria Pharmaceuticals, Cytokinetics, AXA Investment Managers and 5 others
•
Novo-Backed Crystalys Debuts With $205M to Tackle GoutBioSpace•Sep 30, 2025•Crystalystx, AN Venture Partners, Catalys Pacific, KB Investment and 9 others
•
•
•
AN Venture Partners Announces Japan Focused Biotech FundBioSpectrum Asia•Jul 10, 2025•AN Venture Partners
•
VC firm lines up $200M fund to champion Japanese innovationEndpoints•Jul 02, 2025•AN Venture Partners
•
City Therapeutics launches with $135m Series A fundingPharmaceutical Technology•Oct 09, 2024•City Therapeutics, Arch Venture Partners, Fidelity Investments, Invus and 6 others
•
Japan's Otsuka Pharma enters into $30 M investment contract with AN Venture PartnersBioSpectrum Asia•Mar 01, 2024•Otsuka Pharmaceutical, AN Venture Partners
